$ZLAB

Lis William sold $213K of ZLAB

Lis William sold 8,506 shares of Zai Lab Ltd (ZLAB) at $25.00 ($0.21M total) on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lis William
Published Aug 13, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ZLAB
Neutral
high confidence
Mentioned
$ZLAB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

The disclosed sale amount ($212,650) is specific and new, but it is not a corporate action or operational update. The most actionable takeaway is monitoring for any pattern of insider activity alongside future company-specific catalysts.

02

Market read

Traders may log the transaction for sentiment tracking, but it is unlikely to drive a standalone trading decision without additional company news.

03

What to watch

The article provides only the sale details, not whether there were concurrent buys, option exercises, or other corporate developments that could contextualize the transaction.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-08-13, covering a sale dated 2026-08-12.

Background

The article is a SEC Form 4 insider transaction disclosure for Zai Lab Ltd, reporting an open-market sale by a director under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$ZLABNeutralHigh confidence
Context

Zai Lab director Lis William filed a Form 4 open-market sale of 8,506 shares at $25.00 on 2026-08-12 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move based solely on this disclosure.

Evidence & confidence

The filing is an insider transaction (not an earnings, guidance, deal, or regulatory event) and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may watch for clustering of sales around other negative catalysts.

Key entities

  • Zai Lab Ltd

    Public company subject of the Form 4 insider transaction disclosure.

  • Lis William

    Director who sold 8,506 shares at $25.00 under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZLABMedAI 9/10

How Investors Are Reacting To Zai Lab (ZLAB) Phase 3 VYVGART Hytrulo Autoimmune Myositis Data

Zai Lab (ZLAB) and Argenx reported positive Phase 3 results for VYVGART Hytrulo in treating autoimmune myositis, showing significant improvements over placebo. The data suggest potential for the drug in a market currently dominated by corticosteroids. Analysts highlight the importance of execution on recent launches and China's pricing pressures. Some analysts predict modest revenue growth and continued losses by 2029.

$ARGXMedAI 9/10

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Argenx (ARGX) and Zai Lab (ZLAB) reported positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. ARGX saw a 15% stock rise and a $1,100 price target from RBC. ARGX reported Q2 2026 revenue of $1.516B, up 60% YoY, while ZLAB reported $106.3M revenue, down 3% YoY. ARGX has a stronger financial position with $5.2B in cash, while ZLAB has $717.5M. Investors should watch FDA decisions and ZLAB's commercial execution.

$ZLABMedAI 8/10

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Zai Lab (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) reported positive topline Phase 3 ALKIVIA results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis. The study met the Week 52 primary endpoint in the combined IMNM and DM population (p=0.0011), with mean Total Improvement Score 47.95 vs 32.56 vs placebo. IMNM also met (p=0.0048); DM did not reach significance (p=0.1093).

$ZLABMedAI 8/10

Zai Lab, argenx report positive Phase 3 ALKIVIA results

Zai Lab and argenx reported positive Phase 3 ALKIVIA results for VYVGART Hytrulo (efgartigimod). At Week 52, mean TIS improved 15.4 points more than placebo (p=0.0011), with benefits starting by Week 4 and persisting through one year despite steroid tapering. Zai Lab shares were about 0.3% lower premarket at $25.90.

$ZLABMedAI 8/10

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

Zai Lab (ZLAB) reported Q2 2026 revenues of $106.3 million, down from $110.0 million a year earlier. Net product revenue was $105.8 million, up 11% sequentially, with growth tied to VYVGART and stabilization of ZEJULA. Net loss was $50.8 million ($0.05/share). Cash was $717.5 million at June 30, 2026. Management discussed Zoci and VYVGART timelines and supply constraints.

$ZLABMed

Zai Lab Q2 Earnings Call Highlights

Zai Lab (NASDAQ:ZLAB) said it plans to seek China NRDL inclusion for VYVGART HYTRULO and shift the VYVGART franchise from IV to subcutaneous. Management flagged timing effects on second-half revenue, aims to stabilize revenue before stronger 2027 growth, and reported $717.5M cash. It outlined zoci ADC Phase III plans and pipeline updates.